pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
21d
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
fiercebiotech
21d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
21d
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
21d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
21d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
21d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
21d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
21d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
21d
Flagship blends three biotech startups to form Etcelera
biopharma dive
21d
Opinion: Health care needs buyers willing to say no
stat
21d
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
stat
22d
Flagship brings 3 biotech platforms together to launch AI drug discovery player Etcelera
fiercebiotech
22d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
22d
STAT+: Senate candidate El-Sayed wants to ‘grill’ RFK Jr., calls him the ‘most incompetent HHS secretary ever’
stat
22d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
22d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
22d
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
biospace
22d
What has actually caused the decline in drug overdose deaths?
stat
22d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
22d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
22d
Biogen CEO tells analysts he’s focused on early-stage R&D as ‘we were not very good with that’
fiercebiotech
22d
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
stat
22d
Opinion: Freezing my eggs showed me just how anti-feminist the fertility industry can be
stat
22d
Have you been impacted by Epic’s actions?
stat
22d
Opinion: How pediatricians like me are helping families stay calm and informed about measles
stat
22d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
22d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
23d
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
stat
23d
‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 days
fiercebiotech
23d
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
biopharma dive
← prev
page 5 of 34
next →